MORGANTOWN PULMONARY ASSOCIATES, P.C.
Roger A. Abrahams, M.D., FCCP
Andrzej J. Jaworski, M.D., FCCP, D.A.B.S.M.

1265 Pineview Drive
Morgantown, WV 26505

Phone 304-598-2077
Fax 304-598-3717

Pulmonary Diseases
Critical Care
Sleep Medicine
Occupational Lung Disease

[redacted]

CURRICULUM VITAE

NAME: **ROGER A. ABRAHAMS, M.D., F.C.C.P.**

DATE OF BIRTH: [redacted]

HOME ADDRESS: [redacted]

BUSINESS ADDRESS: Morgantown Pulmonary Clinical Research
1265 Pineview Drive
Morgantown, WV 26505

GRADUATE TRAINING:

Fellowship in Pulmonary Medicine Saint Vincent Hospital Major Affiliate: University of Massachusetts Medical School	1983-1985
Residency in Internal Medicine Stamford Hospital, Stamford, Connecticut Major Affiliate: New York Medical College Chief Resident: 8/82 - 1/83	1981-1983
Internship in Internal Medicine Long Island Jewish Medical Center New Hyde Park, NY Major Affiliate: State University of New York at Stonybrook	1979-1980

EDUCATION:

Medical:	State University of New York at Stonybrook Queens Hospital Center 5th Pathway	1978-1979

	Autonomous University of Guadalajara Mexico; M.D.	1974-1978
Pre-Medical:	Alfred University, NY B.A. Cum Laude – Chemistry	1969-1973

PROFESSIONAL EXPERIENCE:

Clinical Research **Morgantown Pulmonary Clinical Research** **Owner/Principal Investigator** 1265 Pineview Drive Morgantown WV 26505	1995-Present
Independent Contractor **Outpatient Pulmonary Physician** Mon Health Pulmonary Care 1000 Mon Health Medical Park Dr. Morgantown, WV 26505 And Stonewall Jackson Memorial Hosp., Weston, WV.	4/2016-Present
Private Practice **President** **Morgantown Pulmonary Associates, P.C.** 1265 Pineview Drive Morgantown, WV 26505	1987-3/2016
Clinical Associate Professor of Medicine **West Virginia University** Department of Medicine Section of Pulmonary and Critical Care Robert C. Byrd Health Sciences Center Morgantown, WV 26506-9156	7/01-Present
NIOSH Certified B-Reader	1986-Present
Executive Committee **Monongalia General Hospital** 1200 J. D. Anderson Drive Morgantown, WV 26505	11/98-10/2009
Chief, Section of Pulmonary Medicine **Monongalia General Hospital**	12/00-2010

President Medical Staff 1/06-1/07
Health South Regional Rehabilitation Hospital
1160 Van Voorhis Road
Morgantown, WV 26505

Vice President Medical Staff 1/05-1/06
Health South Regional Rehabilitation Hospital

Executive Committee 1994-1998
Health South Regional Rehabilitation Hospital

Chief of Department of Medicine 1/90-1/92
Monongalia General Hospital

Private Practice 4/87-8/87
Pulmonary and Occupational Lung Disease
1197 Van Voorhis Road
Morgantown, WV 26505

Medical Director 1987-1988
West Virginia Society for
Respiratory Therapy, Chapter II

Private Practice 1985-1987
Pulmonary and Occupational Lung Disease
Internal Medicine Associates, Inc.
99 J. D. Anderson Drive
Morgantown, WV 26505

Medical Director 1986-1987
Pulmonary Rehabilitation
Monongalia General Hospital

Prior to 1986 upon Request

PRESENTATIONS/PUBLICATIONS

(See Publication Attachment)

Speaker for Sunovion **2017-Present**
Speaker for Astra Zeneca **2016-Present**
Speaker for GSK **2009-Present**

CLINICAL RESEARCH,
PRINCIPAL INVESTIGATOR:
Morgantown Pulmonary
Clinical Research

2017-2019 GSK: "A 24-week multi-center, randomized, double blind, double dummy, 3-arm study to compare Umeclidinium/Vilanterol (Anoro), Umeclidinium (Incruse), and Salmeterol (Serevent) in subjects with chronic obstructive pulmonary disease (COPD)." (Protocol GSK2017490.

2017- completed GSK: "A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidimium, and Salmeterol in subjects with chronic obstructive pulmonary disease (COPD)." (protocol # GSK201759).

2016- completed GSK: "A Randomized, Open-Label, 8-Week Cross-Over Study to Compare Umeclidinium/Vilanterol with Tiotropium/Olodaterol Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)." (protocol GSK204990).

2015- completed GSK: "Study MEA117113: Mepolizumab VS. Placebo as add-on treatment for fequently exacerbating COPD patients characterized by eosinophil level"

2015- completed Boehringer Ingelheim: " A randomised, double-blind, active-controlled parallel group study to elvaluate the effect of 52 weeks of once daily treatment of orally inhled tiotropium + olodaterol fixed does combination compared with tiotropium on Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with severe to very severe COPD. (DYNAGITO) (protocol #1237.19)

2015– completed Pearl: "A Randomized, double-Blind, Multi-Center, Parallel Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbation over a 52-week Treatment Period in Subjects With Moderate to Very Severe COPD." (protocol #PT10005-01)

2015– completed Pearl: "A Randomized, Bouble-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003 and PT009 compared with Symbicort Turbuhaler as and Active Control in subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease." (protocol #PT010006-00)

2014-completed Astra Zeneca "A randomised, double-blind, double dummy, placebo-controlled, parallel group, multicentre, phase III study to evaluate the efficacy and safety of 3 doses of benralizumab (MEDI-563) in patients with severe to very severe Chronic Obstrutive Pulmonary disease (COPD) with a history of COPD exacerbations" (TERRANOVA) (protocol #D3251C00004)

2014-2015 GSK "A 4-Week Study to Evaluate Four Doses of Umeclidinium Bromide in Combination with Fluticasone Furoate in COPD Subjects with an Asthmatic Component"(protocol # 200699).

2014 Boehringer-Ingelheim: "A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium + olodaterol fixed dose combination (delivered by the Respimat® inhaler) in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)" [OTEMTO™2] (protocol # 1237.26).

2013-2014 GSK: "A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VI in subjects with Chronic Obstructive Pulmonary Disease (COPD)" (protocol # 200109).

2012-2014 **Coordinating Investigator,** Boehringer-Ingelheim:
"A randomize, double-blind, parallel group study to assess efficacy and safety of 12 weeks of once daily treatment of orally inhaled Olodaterol 5 mcg (delivered by the Respimat inhaler) added to tiotropium 18 mcg (delivered by the HandiHaler) compared to placebo (delivered by the Respimat inhaler) added to tiotropium 18 mcg (delivered by the HandiHaler) in patients with chronic obstructive pulmonary disease (COPD)" (protocol #1222.51).

2012- 2013 Forest Research: A phase III, long-term, randomize, double blind, extension study of the efficacy, safety and tolerability of 2 fixed dose combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and placebo for 28 weeks treatment in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD)" (protocol #LAC-MD-36).

2012- 2014 Boehringer Ingelheim: "A randomize, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + Olodaterol fixed dose combination (2.5 mcg/5 mcg; 5 mcg/5 mcg) (delivered by the Respimat inhaler) compared with the individual components (2.5 mcg and 5 mcg tiotropium, 5 mcg Olodaterol) (delivered by the Respimat inhaler) in patients with chronic obstructive pulmonary disease (COPD). [TOnado TM 1]" (protocol #1237.5).

2012 PEARL Therapeutics: "A randomize, double blind, (test products), chronic dosing (7 days), four-period, eight treatment, incomplete block, crossover, multicenter study to assess efficacy and safety of 5 doses of PT 003, one dose of PT 001 and one dose of PT 005 in patients with moderate to severe COPD, compared with Spiriva HandiHaler (tiotropium bromide 18 mcg, open label) as active-controlled" (protocol #PT 003005-00).

2011-2012 Forest Laboratories: "A phase III, randomized, double blind, placebo controlled study evaluating the efficacy, safety, and tolerability of 2 fixed dose combination of Aclidinium Bromide/Formoterol Fumarate Compared with Aclidinium Bromide, Formoterol Fumarate and placebo for 24 weeks in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD)" (protocol #LAC-MD-31).

2011-2012 Glaxo SmithKline: "A 52 week, multicenter, randomize, double blind, parallel group, placebo controlled study to evaluate the safety and tolerability of GSK 573719 125 mcg once daily alone and in combination with GW 642444 25 mcg once daily via novel dry powder inhaler (nDPI) in subjects with chronic obstructive pulmonary disease (COPD)" (protocol #DB 2113359).

2011-2012 Glaxo SmithKline: "A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with tiotropium over 24 weeks in subjects with COPD (protocol #DB 211-3374)."

2010- 2012 Glaxo SmithKline: "A long-term safety study of GSK573719 alone and in combination with GW642444 compared with placebo in subjects with COPD (protocol #DB2113359) ".

2009-2010 Boehringer-Ingelheim: "Phase III, one-year, randomized, open-label safety and patient acceptability study of Combivent® Respimat® (ipratropium bromide and albuterol sulfate) (20/100 mcg) Inhalation Spray in comparison to Combivent® Inhalation Aerosol (36/206 mcg) and the free combination of Atrovent® HFA (ipratropium bromide HFA) Inhalation Aerosol (34 mcg) and albuterol HFA inhalation aerosol
(180 mcg) in adults with chronic obstructive pulmonary disease (COPD) (protocol #BI 1012.62)"

2009-2010 Pifzer: "A Phase 2B, parallel, double blind, double dummy, active comparator and placebo controlled study to investigate the Safety, Toleration and Efficacy of 6-week QD administration of PF-00610355 CRC-749 DPI in patients with moderate COPD (protocol #A7881013)".

2009-2010 Glaxo SmithKline: "A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared with Placebo in Subjects with Chronic Obstructive Pulmonary Disease (COPD) HZC112207".

2009-2010 Boehringer-Ingelheim: "Randomize, double blind, placebo controlled, parallel group study to assess the efficacy and safety of 48 weeks of once daily treatment of orally inhaled BI 1744 CL (5 mcg [2 actuations of 2.5 mcg] and 10 mcg [2 actuations of 5 mcg]) delivered by the Respimat inhaler, in patients with chronic obstructive pulmonary disease (COPD) (protocol #1222.12)".

2009-2010 Glaxo SmithKline: "A Randomized, Double-Blind, Parallel-Group, 16-Week Study to Evaluate the Effect of Fluticasone Propionate/Salmeterol DISKUS™ 250/50mcg BID and Placebo on Arterial Stiffness in Subjects with Chronic Obstructive Pulmonary Disease (COPD) (protocol #ADC112355) ".

2007-2009 Glaxo SmithKline: "A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma (protocol #ADA109057)".

2007-2009 **Coordinating Investigator,** Boehringer-Ingelheim: **"**A multinational, randomized, double-blind, placebo- and active-controlled, parallel group efficacy and safety comparison over 24 weeks of three doses (50 μg , 100 μg, 200 μg) of BEA 2180 to tiotropium 5 μg and placebo delivered by the Respimat® inhaler in patients with chronic obstructive pulmonary disease (COPD) (protocol #1205.14**)".**

2008-2009 Boehringer-Ingelheim: "Randomize, double blind, parallel group study to assess the efficacy and safety of 4 weeks of once daily treatment of 3 doses of orally inhaled BI 1744CL, each in fixed dose combination with 5 mcg tiotropium bromide (delivered by the Respimat inhaler) compared with 5 mcg tiotropium bromide mono product (delivered by the Respimat inhaler) in patients with COPD (protocol number BI 1237.4)".

2008-2009 Glaxo SmithKline: "A Randomize, Double Blind, Double Dummy, Parallel Group 12 Week Comparison of the Efficacy and Safety of Fluticasone Propionate/Salmeterol Hydrofluoalkane 134 a Metered-Dose Inhaler 230/42 Mcg Twice Daily with Fluticasone Propionate/Salmeterol Diskus 250/50 Mcg Twice Daily in Subjects with COPD (Protocol #ADC 111117) ".

2007-2008 Boehringer-Ingelheim: "A 24 Week (+24 Week Extension), Randomize, Placebo Controlled (Only First 12 Week Period), Double Blind, Parallel Group, Efficacy and Safety Comparison of Tiotropium/Salmeterol (7.5 Mcg/25 Mcg) Inhalation Powder in the Morning (PE Capsule Via Tiotropium/Salmeterol HandiHaler), Tiotropium (18 Mcg) Inhalation Powder in the Morning (Gelatin Capsule Via Spiriva HandiHaler), Salmeterol Inhalation (25 Mcg) Powder in the Morning and Evening (PE Capsule Via Tiotropium/Salmeterol HandiHaler) and Tiotropium/Salmeterol (7.5 Mcg/25 Mcg) Inhalation Powder in the Morning (PE Capsule Via Tiotropium/Salmeterol HandiHaler) Plus Salmeterol (25 Mcg) Inhalation Powder in the Evening (PE

Capsule Via Tiotropium/Salmeterol HandiHaler) in Patients with COPD (Protocol #1184.15) ".

2007-2008 Novartis: "A 12 Week Treatment, Multicenter, Randomize, Double Blind, Placebo Controlled, Parallel Group
Study to Assess the Efficacy and Safety of Indacaterol (150 Mcg O. D.) In Patients with Chronic Obstructive Pulmonary Disease (Protocol #CQAB 149B 2346) ".

2007 Dey: "A Randomize, Open Label, 2-Way Crossover Trial of Formoterol Fumarate Inhalation Solution (20 Mcg) and
Combivent Inhalation Aerosol (Ipratropium Bromide 18 Mcg/Albuterol Sulfate 103 Mcg) in the Treatment of Patients with Chronic Obstructive Pulmonary Disease (Protocol #201-081)".

2006-2007 Sepracor: "A Two-Week, Randomized, Modified-Blind, Double-Dummy, Parallel-Group Efficacy and Safety Study of Arformoterol Tartrate Inhalation Solution Twice-Daily, Tiotropium Inhalation Powder Once-Daily, and Arformoterol Tartrate Inhalation Solution Twice-Daily and Tiotropium Inhalation Powder Once-Daily (Dosed Sequentially) in
Subjects with Chronic Obstructive Pulmonary Disease."(COPD) (Protocol 091-902).

2006-2007 Boehringer Ingelheim: "A comparison of ipratropium bromide/salbutamol delivered by the Respimat® inhaler to COMBIVENT® Inhalation Aerosol and ipratropium bromide delivered by the Respimat® in a 12-week, double-blind, safety and efficacy study in adults with chronic obstructive pulmonary disease." (COPD) (Protocol 1012.56).

2006-2007 Adams: "A Randomized, Double-Blind, Parallel-Group, Multiceneter, Placebo-Controlled Dose-Ranging Study of Erdosteine for the Treatment of Stable Chronic Bronchitis Associated with Chronic Obstructive Pulmonary disease." (Chronic Bronchitis) (Protocol ERD-CB-01-2005).

(Prior Studies Upon Request)

TEACHING APPOINTMENTS:

Clinical Associate Professor 2001-Present
Department of Medicine
Section of Pulmonary Diseases
West Virginia University Medical School
Morgantown, WV 26505

Clinical Instructor 1987-2001
Department of Medicine
Section of Pulmonary Diseases
West Virginia University Medical School
Morgantown, WV 26505

	Visiting Professor Department of Pulmonary Medicine Autonomous University of Guadalajara Medical School, Mexico	9/86 & 8/87
	Instructor: Department of Medicine 1984-1985 Division of Pulmonary Medicine University of Massachusetts Medical School Worcester, MA	
	Instructor: Quinsigamond Community College, Department of Respiratory Therapy Worcester, MA	1984-1985
HONORS/AWARDS:	Annual Scientific Essay Contest Long Island Jewish Medical Center and Queens Hospital: Third Prize	1979
	"Best Medical Student Award" Class of 1978	1978
	Phi Kappa Phi National Honor Society	1973
	Blue Key National Honor Society	1973
CERTIFICATIONS:	American Board of Internal Medicine Sub-specialty Board in Pulmonary Diseases	1988
	NIOSH Certified "B" Reader	1986-Present
	American Board of Internal Medicine	1983
	Advanced Cardiac Life Support	1980
	Federal Licensing Exam - New York	1979
	Examination Commission for Foreign Medical Graduates	1977
LICENSURE:	Pennsylvania West Virginia Massachusetts New York	1988 1985 (active) 1984 1979

PROFESSIONAL SOCIETIES:

American Thoracic Society
Fellow, American College of Chest Physicians
American College of Physicians
West Virginia Thoracic Society
West Virginia Medical Society
Monongalia County Medical Society
Tri State Chest Physicians Association
American Medical Association

OTHER LANGUAGES: Spanish

PERSONAL INTERESTS:

Photogrophy
Sailing
Cycling
Backpacking

REFERENCES: Available on request